In Our Control (62 page)

  
61.
Lippman et al., “Human Papillomavirus,” 485.

  
62.
Charlotte J. Haug, “Human Papillomavirus Vaccination—Reasons for Caution,”
New England Journal of Medicine
359, no. 8 (August 21, 2008): 861.

  
63.
Lopes, “HPV Vaccine Concerns,” A01.

  
64.
Diana Zuckerman, interview with author, October 20, 2009.

  
65.
Ibid.

  
66.
Rachel L. Winer et al., “Genital Human Papillomavirus Infection: Incidence and Risk Factors in a Cohort of Female University Students,”
American Journal of Epidemiology
157, no. 3 (2003): 218–26.

  
67.
Rachel L. Winer et al., “Condom Use and the Risk of Genital Human Papillomavirus Infection in Young Women,”
New England Journal of Medicine
354, no. 25 (June 22, 2006): 2645.

  
68.
Lindsey R. Baden et al., “Human Papillomavirus Vaccine—Opportunity and Challenge,”
New England Journal of Medicine
356, no. 19 (May 10, 2007): 1190–91.

  
69.
Haug, “Human Papillomavirus Vaccination,” 861.

  
70.
Doctor Gifford-Jones, “Guard against STDs and Cancer Deaths,”
Toronto Sun
, April 14, 2007, 30.

  
71.
“Merck’s Gardasil Hits a Snag,”
Wall Street Journal
, January 12, 2009, B4.

  
72.
“FDA Rejects Wider Patient Age Group for Merck & Co’s Gardasil,”
Pharma Marketletter
, June 26, 2008.

  
73.
Janelle Miles, “Pap Smears Better Than Vaccines for Older Women, Says Doctor,”
Courier-Mail
(Queensland), May 5, 2008, 11.

  
74.
Rita Rubin, “O Babies, Where Are Thou?”
USA Today
, July 3, 2008, 4D.

  
75.
Ginsberg, “Glaxo Asks Cervarix Approval,” C01.

  
76.
Matthew M. Davis et al., “Childhood Vaccine Purchase Costs in the Public Sector: Past Trends, Future Expectations,”
American Journal of Public Health
92, no. 12 (December 2002): 1982–87; Andrew Pollack, “In Need of a Booster Shot; Rising Costs Make Doctors Balk at Giving Vaccines,”
New York Times
, March 24, 2007, C1.

  
77.
Miriam Hill, “Gardasil for Males? Report Hikes Hopes,”
Philadelphia Inquirer
, November 14, 2008, D01.

  
78.
Maria Moscaritolo, “Is It Safe to Inject Our Girls?”
Advertiser
(South Australia), May 24, 2007, 21.

  
79.
Quoted in Melinda Tankard Reist and Renate Klein, “Why Are We Experimenting with Drugs on Australian Girls?”
Age
(Melbourne), May 25, 2007, 13.

  
80.
“Activist Group Reveals Gardasil AE Data,”
Pharma Marketletter
, May 31, 2007.

  
81.
Gina S. Ogilvie et al., “Parental Intention to Have Daughters Receive the Human Papillomavirus Vaccine,”
Canadian Medical Association Journal
177, no. 12 (December 4, 2007): 1506.

  
82.
Charlie Fidelman, “Vaccination Push Failing in Ontario,”
Gazette
(Montreal), November 22, 2007, A8.

  
83.
André Picard, “Why Politics and Public Health Don’t Mix,” L6.

  
84.
Rebecca Smith, “Two Girls Die after Cervical Cancer Jab,”
Daily Telegraph
(London), January 25, 2008.

  
85.
“Clinical Brief: Gardasil to Continue,”
Chemist and Druggist
, February 28, 2009.

  
86.
Anne Karpf, “The State Wants My Daughter to be Vaccinated, but I Want to Know More,”
Guardian
(London), March 1, 2008, 5.

  
87.
Ian Munro with Nick Miller, “Link between Cancer Jabs and Deaths in US Rejected,”
Age
(Melbourne), July 2, 2008, 11.

  
88.
Julia M. L. Brotherton, et al., “Anaphylaxis Following Quadrivalent Human Papillomavirus Vaccination,”
Canadian Medical Association Journal 179
, no. 6 (September 9, 2008): 525–33.

  
89.
Ibid., 529.

  
90.
Neal A. Halsey, “The Human Papillomavirus Vaccine and Risk of Anaphylaxis,”
Canadian Medical Association Journal 1
79, no. 6 (September 9, 2008): 509.

  
91.
Amy Fagan, “Merck, FDA Expand Gardasil Warnings,”
Washington Times
, July 10, 2008, A03.

  
92.
Louise Hall, “Cancer Jab Linked to Pancreas Disease,”
Canberra Times
, August 17, 2008, 14.

  
93.
“NVIC [National Vaccine Information Center] Says Government Denies Gardasil Risks,”
Drug Week
, November 14, 2008, 2111.

  
94.
“Guillain-Barre Syndrome,” Mayo Clinic, May 30, 2009,
http://www.mayoclinic.com/health/guillain-barre-syndrome/DS00413
.

  
95.
Halsey, “Human Papillomavirus Vaccine,” 510.

  
96.
“Sting in Cancer Shot: Girls Report Pain from Gardasil Vaccine,”
Herald Sun
(Melbourne, Australia), January 5, 2008.

  
97.
From the Centers for Disease Control and Prevention, Morbidity and Mortality Weekly Report, “Syncope after Vaccination—United States, January 2005–July 2007,”
Journal of the American Medical Association
229, no. 21 (June 4, 2008): 2505.

  
98.
Quoted in Alexandra M. Stewart, letter to the editor, “Mandating HPV Vaccination—Private Rights, Public Good,”
New England Journal of Medicine
356, no. 19 (May 10, 2007): 1998.

  
99.
Lee Hui Chieh, “Safe to Use New Cervical Cancer vaccine,”
Straits Times
(Singapore), April 4, 2007.

100.
Ogilvie et al., “Parental Intention,” 1506.

101.
R. Alta Charo, “Politics, Parents, and Prophylaxis—Mandating HPV Vaccination in the United States,”
New England Journal of Medicine
356, no. 19 (May 10, 2007): 1907.

102.
Karpf, “The State Wants My Daughter to Be Vaccinated,” 5.

103.
Ibid.

104.
Gostin and DeAngelis, “Mandatory HPV Vaccination,” 1921–23.

105.
Elizabeth Leyland, “Human Papillomavirus Vaccination: Stabbing in the Dark?”
Lancet
372, no. 9639 (August 23, 2008): 614.

106.
Johnston, “Our Very Modern Dilemma,” 26; Fry-Revere, “The Rush to Vaccinate,” 17.

107.
Gostin and DeAngelis, “Mandatory HPV Vaccination,” 1921–23.

108.
Quoted in Dawn Rae Downton, “A Cancer Vaccine with Political Will; Marketing Conquers Science, HPV Critics Say,”
National Post
(Ontario), August 7, 2007, A1.

109.
Carole R. McCann,
Birth Control Politics in the United States
(Ithaca, NY, and London: Cornell University Press, 1994), 44.

110.
Quoted in Amy Luft, “Justify Your Existence: Abby Lippman. The Canadian Women’s Health Network Has Some Concerns about the Government’s Plan to Offer Mass Inoculations against HPV; Has the HPV Vaccine Been Overhyped?”
Gazette
(Montreal), April 26, 2008, B2.

111.
Marisa Treviño, “Immigrants Given No Choice on Vaccine,”
USA Today
, October 17, 2008, 11A.

112.
Quoted in Mary Engel, “Immigrants’ Advocates Decry Gardasil Requirement,”
Los Angeles Times
, October 22, 2008, A9.

113.
Quoted in ibid.

114.
Abigail Shefer et al., “Early Experience with Human Papillomavirus Vaccine Introduction in the United States, Canada and Australia,”
Vaccine
26, suppl. 10 (August 19, 2008): K69.

115.
Rosenthal, “Drug Makers’ Push,” A1.

116.
Thomas H. Maugh II, “Cervical Cancer Vaccination Rate at 25%, U.S. Says,”
Los Angeles Times
, October 10, 2008, A17.

117.
Mona Saraiya et al., “Cervical Cancer Incidence in a Prevaccine Era in the United States, 1998–2002,”
Obstetrics & Gynecology
109, no. 2, pt. 1 (February 2007): 360–70.

118.
Rosenthal, “Drug Makers’ Push,” A1.

119.
Maggie Fox, “Merck-Sponsored Study Suggests HPV Vaccine Benefits Men Too,”
Globe and Mail
(Toronto), November 14, 2008, L4.

120.
Quoted in James Cowan, “HPV Vaccine Prevents Genital Lesions in Men, Merck Study Claims; Market Expansion?”
National Post
(Ontario), November 14, 2008, A6.

121.
Email to the author, October 21, 2009.

122.
Stina Syrjänen, “Human Papillomaviruses in Head and Neck Carcinomas,”
New England Journal of Medicine
356, no. 19 (May 10, 2007): 1994.

123.
Zerbisias, “Pap smears Are First Line of Defense,” L02.

124.
Jan Hoffman, “Vaccinating Boys for Girls’ Sake?”
New York Times
, February 24, 2008, Fashion & Style section, 1,
http://www.nytimes.com/2008/02/24/fashion/24virus.html
.

125.
Quoted in ibid.

126.
Sue J. Goldie et al., “Cost-Effectiveness of Cervical-Cancer Screening in Five Developing Countries,”
New England Journal of Medicine
353, no. 20 (November 17, 2005): 2158–68.

127.
Mark Schiffman and Philip E. Castle, “The Promise of Global Cervical-Cancer Prevention,”
New England Journal of Medicine
353, no. 20 (November 17, 2005): 2101–4.